Selective estrogen receptor modulators

1. A compound of Formula (I):

or pharmaceutically acceptable salt form thereof,

wherein R 1 is

R 2 and R 3 , together with the atoms to which they are attached, form a seven-membered ring structure where the atoms forming the ring are carbon atoms;

R 4 is selected from H, OH, C 1-8 alkyl, OC 1-8 alkyl, and halo;

R 5 is selected from H, OH, CN, nitro, C 1-8 alkyl, OC 1-8 alkyl, and halo;

R 6 is selected from H, OH, CN, OC 1-8 alkyl, methyl, ethyl, propyl and butyl;

X is selected from the group consisting of O, or NH, wherein when X is O, R 6 is other than OH; and

the bond represented by a broken line and a solid line is an optional double bond.

2. A compound of Formula (I):

or pharmaceutically acceptable salt form thereof,

wherein R 1 is

R 2 and R 3 , together with the atoms to which they are attached, form a seven-membered ring structure where one or more of the atoms forming the ring are oxygen;

R 4 is selected from H, OH, C 1-8 alkyl, OC 1-8 alkyl, and halo;

R 5 is selected from H, OH, CN, nitro, C 1-8 alkyl, OC 1-8 alkyl, and halo;

R 6 is selected from H, OH, CN, OC 1-8 alkyl, methyl, ethyl, propyl and butyl;

X is selected from the group consisting of O, or NH, wherein when X is O, R 6 is other than OH; and

the bond represented by a broken line and a solid line is an optional double bond.

3. A compound according to claim 1 , wherein R 1 is —C(═O) OH.

4. A compound according to claim 3 , wherein the bond represented by a broken line and a solid line is a double bond.

5. A compound according to claim 1 , wherein R 4 and R 5 are each independently H.

6. A compound according to claim 1 , wherein R 4 is OH and R 5 is H.

7. A compound according to claim 1 , wherein R 4 is OCH 3 and R 5 is H.

8. A compound according to claim 1 , wherein R 4 is OH and R 5 is OH.

9. A compound according to claim 1 , wherein R 4 is H and R 5 is OH.

10. A compound selected from:

a) 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

b) 3-{4-[6-(4-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

c) 3-{4-[6-(3-Hydroxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

d) 3-{4-[6-(4-Hydroxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

f) 3-[4-(6-Phenyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)-phenyl]-acrylic acid;

g) 3-[4-(2-Hydroxy-6-phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acrylic acid;

h) 3-{4-[2-Hydroxy-6-(3-hydroxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

i) 3-{4-[2-Hydroxy-6-(4-hydroxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid;

r) 3-[4-(3-Phenyl-2H-chromen-4-yl)-phenyl]-acrylic acid;

s) 3-[4-(2-Phenyl-3,4-dihydro-naphthalen-1-yl)-phenyl]-acrylic acid;

t) 3-[4-(2-Phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-phenyl]-acrylic acid; and

u) 3-[4-(6-Phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-acrylic acid.

11. 3-[4-(6-Phenyl-8,9-dihydro-7H-benzocyclohepten-5-yl)-phenyl]-propionic acid, or a pharmaceutical acceptable salt form.

12. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier in combination with a therapeutically effective amount of at least one compound of claim 1 .

13. A method of treating breast, uterine, ovarian, prostate, or colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; or urinary incontinence, comprising:

administering to a host in need of such treatment a therapeutically effective amount of at least one compound of claim 1 .